We have a digital-to-physical workflow to develop custom targeted phage products to tricky bacteria (drug-resistant, biofilm-forming, etc.). We have proven our computational phage discovery pipeline works against all ESKAPE pathogens + C. difficile. Our phage engineering platform yields targeted phage by design rather than by chance, resulting in a much shorter turnaround time than typical phage discovery workflows and the ability to update and improve phage collections with low cost. Proof of concept in bacteria affecting human health, animal health, and food safety. Seeking partners interested in developing a phage product against a target bacteria or improving their phage collections through engineering.
Biophoundry is a biotechnology company that specializes in developing phage-based technologies to combat antibiotic resistance. The company has built a proprietary platform called Phax, which utilizes cell-free synthetic biology and machine learning to engineer and produce customized bacteriophages—viruses that target and kill specific bacteria—for use in therapeutics, diagnostics, and bio-molecular engineering. By moving from traditional, time-intensive phage discovery to a data-driven, scalable phage design process, the platform aims to provide personalized phage treatments that are significantly faster and more cost-effective to develop and manufacture than existing industry standards.
This technology is intended to support healthcare providers and researchers in addressing the growing global threat of antimicrobial resistance. By offering a rapid, on-demand solution for generating precision antibiotics, Biophoundry seeks to improve patient access to innovative, targeted therapies for recalcitrant infections. The company, headquartered in Chapel Hill, North Carolina, leverages a multidisciplinary team with expertise in systems engineering, synthetic biology, and artificial intelligence to validate their design tools and advance these solutions toward clinical applications.